Drug profile

The FDA adverse-event record for Oxytetracycline Hcl;Polymyxin B Sulfate

19 FDA reports name Oxytetracycline Hcl;Polymyxin B Sulfate, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#1860 of 2,679
by report volume (all drugs)
19
adverse-event reports
5.3%
death-coded share
Unknown
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Oxytetracycline Hcl;Polymyxin B Sulfate ranks #1827 of 2679 by total reports (19). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1827
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Oxytetracycline Hcl;Polymyxin B Sulfate has 19 reports now versus 17 in that prior snapshot: 2 more (11.8%).

Report change
+2
Death-coded reports
+0
Death-coded share
−0.6 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Oxytetracycline Hcl;Polymyxin B Sulfate changes

Signature read: death-coded report count at 1 is the most distinctive stamp on Oxytetracycline Hcl;Polymyxin B Sulfate's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
1
Deaths Reported
5.3%
Death-coded share of reports

Active Ingredients

Oxytetracycline Hcl;Polymyxin B Sulfate

Administration Routes

UnknownOphthalmicIntraocularTopical

Species Affected

Unknown 9
Cat 8
Dog 2

Most Affected Breeds

Unknown 9
Domestic Shorthair 4
Cat (other) 2
Ragdoll 1
Dog (unknown) 1
Norwegian Forest 1
Retriever - Golden 1

Most Reported Reactions

Containers, Leaking 4
Tubes, Leaking 4
Ocular discharge 3
Appearance, Abnormal 2
Eye redness 2
Solution, Abnormal 2
Containers, Damaged 2
Distress 1
Behavioural disorder NOS 1
Hyperactivity 1
Fever 1
Facial swelling (see also Skin) 1

Outcome Breakdown

Ongoing
5 (50.0%)
Recovered/Normal
3 (30.0%)
Died
1 (10.0%)
Outcome Unknown
1 (10.0%)

Oxytetracycline Hcl;Polymyxin B Sulfate: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Oxytetracycline Hcl;Polymyxin B Sulfate (#1860 of 2,679 by report volume); death-coded 5.3%. PlainBreed drug row · death-coded report count stamp 1 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →